SESSION TITLE: ILD Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Pulmonary complications of connective tissue disease (CTD) are common. Recent studies have shown benefit with rituximab (RTX) in the treatment of CTD related interstitial lung disease1,2. We performed a review to assess the benefit of RTX in five patients with pulmonary complications of CTD.
METHODS: Pre- and post-treatment pulmonary function, exercise physiology, echocardiograph and HRCT thorax data were obtained from medical notes and analysed.
RESULTS: Four patients were treated for systemic sclerosis related ILD (SSc-ILD) and one patient had rheumatoid arthritis ILD (RA-ILD). Three patients received RTX after failure of alternate immunosuppression. All 5 patients demonstrated either radiological and/or physiological improvement in response to RTX. No patient had a significant side effect of treatment.
CONCLUSIONS: RTX is a chimeric monoclonal antibody with activity against CD20 expressed by B-cells. Evidence has shown benefit from rituximab used either alone or in conjunction with other immunosuppressive agents. Our patients represent a cohort in whom RTX therapy has been beneficial.
CLINICAL IMPLICATIONS: These results indicate that consideration should be given to RTX therapy in patients with connective tissue disease related pulmonary complications.
DISCLOSURE: The following authors have nothing to disclose: Deirdre Fitzgerald, Sinead Harney, Michael Henry
No Product/Research Disclosure Information